SL
TGTX icon

Salomon & Ludwin’s TG Therapeutics TGTX Stock Holding History

Salomon & Ludwin’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.9K Hold
1,699
– – 0.01% 306
2026
Q1 		$57K Buy
1,699
+711
+72% +$21.2K 0.01% 421
2025
Q4 		$29.5K Buy
988
+65
+7% +$2.12K ﹤0.01% 623
2025
Q3 		$33.9K Buy
+923
New +$30.4K ﹤0.01% 514

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Salomon & Ludwin's TGTX Position: Q2 2026 in Review

Salomon & Ludwin held its TG Therapeutics (TGTX) position steady in Q2 2026 at 1,699 shares worth $90.9K. The position accounts for 0.01% of the portfolio, ranked #306.

Salomon & Ludwin first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Salomon & Ludwin held 1,699 shares of TG Therapeutics worth $90.9K as of Q2 2026.
  • Salomon & Ludwin left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #306 holding.
  • Salomon & Ludwin first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.